Member Info for Soupdragon78

Jiving, it’s pretty clear no one here has ‘inside info’, plenty of folk guessing and trying to sound like they know something.

Jiving, you’ve said ‘Second, the then senior management of NFX mentioned Kissei repeatedly to major shareholders with whom they were in contact’

Interesting, which major shareholders are you talking about?

Jiving, where has the company said they are talking to Kissei?

Juno, the plan is on the website and has been explained by the company.

The issue is more that it doesn’t suit the narrative of those who were pretending that ‘things prepared’ and the ‘deal will be closed shortly’ back in July.

Interesting, so those who were previously saying Blackwell, Keegan and Fleur were the dream team are now saying they don’t want them.

No wonder the company doesn’t want to communicate when people are so fickle.

Whoever it is with these 500k buys is doing a phenomenal job of always getting them at 2.8p

Anyway, back to Gilbert, interesting links to Sosei who even have a presence in Cambridge for those averse to lockdown.

Filter, his last TR1 (24th May 2019) he held 23.5m shares (5.10%).

The website has now been updated which shows he holds 20.75m shares (4.04%). So we can see he has sold 2.75m, at what time we don't know.

Whilst there has been dilution, the placing would have brought his percentage down to 4.5% crossing the threshold down through 5%.

older, Higgins reduced by 2.75m from his holding last year.

When he did this we don't know as he hasn't notified crossing the threshold from 5.1 to 4.04%

Filter, whilst the sp is disappointing, we are close to news on NXP004 which is due by year end. Also half years will show just what revenues have been accrued (I know I'm clinging to optimism there, but I do see them as important in proving the model). Furthermore, Vistagen news is due.
Whilst not the glamour big ticket items, its key to see the business still progressing regardless.

And again the same people who are now saying Covid got in the way, were the same who were saying it wasn't an issue as they knew NFX had an agent in Japan doing the negotiations.

Part of the problem is that everyone is fixated with NXP002 yet there is more than enough within easier reach the rerate the company in the short term. I think Blackwell is realigning the company in this manner.

People keep saying that Kissei will be biting our hand off because its 'their' drug etc, but never seem to acknowledge that exactly the same situation is in play for NXP001, where Merck went out of patent for Emend a while ago and have seen revenues drop by over £100m as a result, and guess what NXP001 is a co-crystal of and outperforms?

Hale, yes, Gilberts key success has been at Acacia which specialises in nausea treatments, he will obviously have connections within this field that could progress markets in NXP001, I get the feeling this is why he has been brought in.

Interesting he has a background in CINV.

The good thing is they are talking ‘near term’

Sonnets, the company set out their key strategies in the prelims. Looks like Gilbert has been brought in to help push these forward.

https://nuformix.com/about-nuformix/strategy/

Wacca. Most go straight to the chat function. Pasting it there just saves people having to go elsewhere.
We don’t have to comment on everything do we?

Just being helpful old boy.

Nuformix PLC

24 November 2020

Nuformix plc

Appointment of Dr Julian Gilbert as Non-Executive Director

Cambridge, UK - 24 November 2020: Nuformix plc (LSE:NFX; "Nuformix", the "Company" or the "Group"), a drug re-purposing specialist, is pleased to announce the appointment of Dr Julian Gilbert to the Board of Nuformix as a Non-Executive Director with immediate effect.

Julian has more than 30 years of commercial and technical experience in the pharmaceutical industry gained at a number of companies including Chiroscience Plc, Mundipharma International Limited, British Technology Group plc (BTG) and Smith Kline & French (now GlaxoSmithKline plc). Most recently, Julian was co-founder and CEO of Acacia Pharma Group plc (Acacia), raising c.GBP100m in private and public funding and leading its flotation on Euronext in 2018. Julian resigned from Acacia on 31 July 2019. Prior to Acacia, he was co-founder and Commercial Director of Arakis Limited which was sold to Sosei in 2005 for GBP107 million. Julian has worked in business development since 1992 and has led multiple business development projects.

Julian has a degree in pharmacy and a PhD in pharmaceutics, both from the University of Nottingham.

Julian will be appointed as a member of the Nomination & Audit Committees.

The Board is also undertaking a search for an additional independent Non-Executive Director with recent and relevant financial experience.

Dr Chris Blackwell, Executive Chairman, commented:

"It's a pleasure for us to welcome Julian to the Board. Julian's knowledge and experience will be extremely valuable as the Company moves forward with its near-term strategic priorities focussed on business development and licensing opportunities. "

Commenting on his appointment, Dr Julian Gilbert said:

"I am delighted to be joining the Board of Nuformix, and look forward to supporting the Company achieve key strategic objectives."

In other news, this video from AstraZeneca is worth a view. They seem keen on IL-33 for some reason.

https://twitter.com/astrazeneca/status/1303368993298931718?s=21

https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/can-improved-understanding-of-the-airway-epithelium-provide-new-insight-into-asthma.html?linkId=99094252

In all fairness it will have been the dilution that pull him down through the threshold, which he should have declared. Then his selling took him from 4.5% to 4.04%